Skip to main content

Published locations for Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients

User login

  • Reset your password
  • /content/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll/sll-patients
  • /fedprac/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll/sll
  • /hematologynews/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll/sll
  • /oncologypractice/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll
  • /fedprac/avaho/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll/sll
  • /jcomjournal/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll/sll
  • /hematology-oncology/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some-cll
  • /b-cell-lymphoma-icymi/article/232966/cll/fixed-duration-ibrutinib/venetoclax-appears-feasible-some